Recurrent Squamous Cell Carcinoma of the Larynx Completed Phase 2 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0028811 (Recurrent Squamous Cell Carcinoma of the Larynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01316757Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerTreatment
NCT00939627Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent CetuximabTreatment